Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: BUY (auto-tracking)
0.00% $9.01
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 11.49 mill |
EPS: | -12.09 |
P/E: | -0.750 |
Earnings Date: | Apr 14, 2024 |
SharesOutstanding: | 1.275 mill |
Avg Daily Volume: | 0.222 mill |
RATING 2024-03-27 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.750 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.750 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
$-7.83 (-186.88%) $-16.84 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 8.59 - 9.39 ( +/- 4.47%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-25 | Cox Katharine Joan | Buy | 0 | |
2023-06-30 | Weingarten Robert N | Buy | 334 | Employee Stock Option (right to buy) |
2023-06-30 | Gagliano Donald A | Buy | 334 | Employee Stock Option (right to buy) |
2023-06-30 | Griggs Michaela | Buy | 334 | Employee Stock Option (right to buy) |
2023-06-30 | Goldstone Mark | Buy | 334 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 85 transactions |
Buy: 9 089 300 | Sell: 335 175 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $9.01 (0.00% ) |
Volume | 0.0041 mill |
Avg. Vol. | 0.222 mill |
% of Avg. Vol | 1.829 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:29 | buy | $8.17 | N/A | Active |
---|
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.